DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NASONEX

Summary for Tradename: NASONEX

Patents:3
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$1,137,402,000
drug
patent expirations by year for
 NASONEX

Pharmacology for Tradename: NASONEX

Clinical Trials for: NASONEX

Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy
Status: Not yet recruiting Condition: Obstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
Status: Completed Condition: Asthma; Airway Inflammation

A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers
Status: Completed Condition: Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Status: Completed Condition: Seasonal Allergic Rhinitis

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
Status: Completed Condition: Asthma

Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)
Status: Terminated Condition: Nasal Obstruction; Adenoids Hypertrophy; Adenoidectomy

A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)
Status: Completed Condition: Rhinitis, Allergic, Perennial

Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
Status: Completed Condition: Perennial Allergic Rhinitis

Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation
Status: Completed Condition: Seasonal Allergic Rhinitis

Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
Status: Suspended Condition: Plaque Psoriasis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
NASONEX
mometasone furoate monohydrate
SPRAY, METERED;NASAL020762Oct 1, 1997RXYes<disabled><disabled>
Merck Sharp Dohme
NASONEX
mometasone furoate monohydrate
SPRAY, METERED;NASAL020762Oct 1, 1997RXYes5,837,699*PED<disabled>Y<disabled>
Merck Sharp Dohme
NASONEX
mometasone furoate monohydrate
SPRAY, METERED;NASAL020762Oct 1, 1997RXYes6,127,353*PED<disabled>Y<disabled>
Merck Sharp Dohme
NASONEX
mometasone furoate monohydrate
SPRAY, METERED;NASAL020762Oct 1, 1997RXYes6,723,713*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NASONEX

Drugname Dosage Strength RLD Submissiondate
mometasone furoateNasal Spray50 mcg/ SprayNasonex8/7/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc